Results
- Showing results for:
- Reset all filters
Search results
-
Journal articleArshad H, Lack G, Durham SR, et al., 2024,
Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease
, JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, Vol: 12, Pages: 45-56, ISSN: 2213-2198 -
Journal articleGoldsmith LP, Roberts A, Flohr C, et al., 2024,
Routine infant skincare advice in the UK: A cross-sectional survey
, CLINICAL AND EXPERIMENTAL ALLERGY, Vol: 54, Pages: 56-60, ISSN: 0954-7894 -
Journal articleMurray SM, Pose E, Wittner M, et al., 2024,
Immune responses and clinical outcomes after COVID-19 vaccination in patients with liver disease and liver transplant recipients
, JOURNAL OF HEPATOLOGY, Vol: 80, ISSN: 0168-8278 -
Journal articleVukmirovic M, Benam KH, Rose JJ, et al., 2024,
Challenges and Opportunities for Commercializing Technologies in the Pulmonary Arena An Official American Thoracic Society Report
, ANNALS OF THE AMERICAN THORACIC SOCIETY, Vol: 21, Pages: 1-11, ISSN: 1546-3222 -
Journal articleDi Pilato V, Codda G, Niccolai C, et al., 2024,
Functional features of KPC-109, a novel 270-loop KPC-3 mutant mediating resistance to avibactam-based ,B-lactamase inhibitor combinations and cefiderocol
, INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, Vol: 63, ISSN: 0924-8579 -
Journal articleTaouli B, Ba-Ssalamah A, Chapiro J, et al., 2024,
Consensus report from the 10th global forum for liver magnetic resonance imaging: multidisciplinary team discussion (may, 10.1007/s00330-023-09919-z, 2023)
, EUROPEAN RADIOLOGY, Vol: 34, Pages: 724-725, ISSN: 0938-7994 -
Journal articleAgirrezabal I, Bouattour M, Pinato DJ, et al., 2024,
Efficacy of transarterial radioembolization using Y-90 resin microspheres versus atezolizumab-bevacizumab in unresectable hepatocellular carcinoma: A matching-adjusted indirect comparison
, EUROPEAN JOURNAL OF CANCER, Vol: 196, ISSN: 0959-8049 -
Journal articleStefani S, Buti N, Hart ACJ, et al., 2024,
Safety and efficacy of SARS-CoV-2 vaccination in patients with immune thrombocytopenia: A two-centre review
, BRITISH JOURNAL OF HAEMATOLOGY, Vol: 204, Pages: 324-328, ISSN: 0007-1048 -
Journal articleCooper N, Ghanima W, Vianelli N, et al., 2024,
Sustained response off-treatment in eltrombopag-treated adult patients with ITP who are refractory or relapsed after first-line steroids: Primary, final, and ad-hoc analyses of the Phase II TAPER trial
, AMERICAN JOURNAL OF HEMATOLOGY, Vol: 99, Pages: 57-67, ISSN: 0361-8609- Cite
- Citations: 11
-
Journal articleAmaral EP, Namasivayam S, Queiroz ATL, et al., 2024,
BACH1 promotes tissue necrosis and Mycobacterium tuberculosis susceptibility
, Nature Microbiology, Vol: 9, Pages: 120-135, ISSN: 2058-5276Oxidative stress triggers ferroptosis, a form of cellular necrosis characterized by iron-dependent lipid peroxidation, and has been implicated in Mycobacterium tuberculosis (Mtb) pathogenesis. We investigated whether Bach1, a transcription factor that represses multiple antioxidant genes, regulates host resistance to Mtb. We found that BACH1 expression is associated clinically with active pulmonary tuberculosis. Bach1 deletion in Mtb-infected mice increased glutathione levels and Gpx4 expression that inhibit lipid peroxidation. Bach1-/- macrophages exhibited increased resistance to Mtb-induced cell death, while Mtb-infected Bach1-deficient mice displayed reduced bacterial loads, pulmonary necrosis and lipid peroxidation concurrent with increased survival. Single-cell RNA-seq analysis of lungs from Mtb-infected Bach1-/- mice revealed an enrichment of genes associated with ferroptosis suppression. Bach1 depletion in Mtb-infected B6.Sst1S mice that display human-like necrotic lung pathology also markedly reduced necrosis and increased host resistance. These findings identify Bach1 as a key regulator of cellular and tissue necrosis and host resistance in Mtb infection.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.